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This report outlines the well defined indications of using IABP and also favours extending the indications of IABP
use, to include not only “therapeutically” the aging unstable patients but also “prophylactically” patients with low EF
or high Euroscore.Introduction
The benefits from the IABP therapy, is due to the sup-
port of the coronary flow [1,2] and the reduction of the
left ventricular load [3]. This reflects in the improvement
of the oxygen supply to demand balance, aiming to re-
duce the size of the ischemic zone and maintain myocar-
dial viability. This outcome leads to transient support of
the left ventricular function in cases of failure during an
ischemic insult. However, the effectiveness of the IABP
depends on the time elapsed since the onset of the myo-
cardial infarction, as well as on the functional stage of
the left ventricle. The frequency of IABP use appears to
be increasing as the proportion of high-risk patients for
cardiac surgery is increasing and the complication rate is
dramatically fallen to an overall rate of 6.5% and a rate
of major complications requiring surgery or transfusion
of 2.1% [4].
And although historically, higher complication rates
have dissuaded clinicians from using it, increasing ex-
perience with favorable results during its earlier use,
broadens the indications of IABP counterpulsation.
The scope of this report is to elude on to the “trad-
itional & extended” indications of its use.Unstable angina not responding to medication (4% of
the cases)
Although the majority of publications are not rando-
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reproduction in any medium, provided the orresponding to the maximum medical treatment can
undergo surgery with stabilization through IABP with a
low surgical mortality rate and low perioperative myo-
cardial infarction rate [5,6].
Gold and associates [7] showed that the use of the
intra-aortic pump eliminates the pain, improves the ST-
segment elevation and prevents ventricular tachyar-
rhythmia. The same group showed that [8] when the
IABP support, is followed by a CABG, then the outcome
is statistically much better. Roberts et al. [9] agree that
in unstable patients with a left ventricular dysfunction,
the use of the IABP allows the safe conduct of diagnostic
studies with a subsequent surgical treatment with a
lower mortality.
Langou et al. [10] in 75 cases of patients where IABP
was used noted a surgical mortality of 5.3% and peri-
operative infarction rate of 6.6%. On the contrary, a
study in 55 patients with a similar presentation, operated
without IABP, 14.5% died during the operation and 29%
suffered a perioperative infarction.Supporting IABP therapy after a myocardial infarction
(24.5% of the cases)
Theoretically, IABP could be used during an acute in-
farction in order to reduce the size and extent of the in-
farct, support the heart function and reduce the
complications related to the incidence. The effects of
IABP in 26 patients with heart failure (following an
MI), were reviewed by O’Rourke et al. In the first group
(n = 12 patients) ischemic pain was observed and a bal-
loon was inserted. The second group (n = 14 patients)Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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was skipped. The effect on the ischemic pain was im-
pressive: the pain stopped within a few minutes for 11
patients and within a few hours for one more patient.
Out of the 14 patients in-group II, 8 in-hospital deaths
occurred.
The same group of researchers [11] in a randomized
clinical study, after reviewing the effect of the balloon in
heart failure following a myocardial infarction, proved
that there is no beneficial effect on the defined end
points (morbidity, mortality). It is now accepted that in
patients with acute infarction no IABP therapy is given,
only as a supportive means followed by myocardial
revascularization, when a cardiogenic revascularization
when cardiogenic shock or any other mechanical com-
plication that follows an infarction occurs. Since reasons
for revascularization are present, the IABP method may
be useful in reducing the size of the infarction and the
surgical mortality [12].
In patients with acute myocardial infarction DeWood
et al. [13] reported the outcomes on 40 patients who
received an IABP therapy for cardiogenic shock after an
infarction. Group I received IABP therapy and Group II
IABP and aortocoronary bypass. Hospital mortality rates
in Groups I and II were 71% and 47% respectively. The
part of Group II that underwent therapy within 16 hours
after the occurrence of the symptoms had lower mortal-
ity rate (25%) than that of Group II that underwent op-
eration later than 18 hours after the symptoms were
manifested (71%). Patients with acute refraction (coron-
ary dissection or refraction due to plaque fissuring) of a
minor branch of the left coronary artery due to percutan-
eous intervention would benefit from the IABP insertion
followed by urgent revascularization [14]. Placement of an
IABP in patients following myocardial infarction was most
frequently indicated for cardiogenic shock (27.3%),
hemodynamic support during catheterization and/or
angioplasty (27.2%) or prior to high-risk surgery (11.2%),
mechanical complications of acute MI (11.7%), and refrac-
tory post-myocardial infarction unstable angina (10.0%)
[15].
Supporting with IABP during the percutaneous coronary
intervention (10.5% of the cases)
The effect of the IABP use during coronary cathe-
terization is reported by Adams et al. [16] to be 1 in
1000.
However with the advent of PCI to include multivessel
angioplasty, several authorities [17] have adopted the
“stand-by” policy during the angioplasty in high risk
patients; furthermore Balloon therapy may be the most
effective treatment in the first minutes following a com-
plicated angioplasty and as per Ferguson et al. [18] the
results from the benchmark registry suggested that themost frequent indications for use of IABP was to provide
hemodynamic support during or after cardiac cathe-
terization (20.6%).
IABP in persistent ventricular fibrillation (4.5% of the
cases)
Almost all ventricular dysrhytmias attributed to ischemia
can temporarily be controlled with medication, so only a
few patients would need IABP insertion prior to a revas-
cularization intervention. In patients with acute ischemia,
when the ventricular fibrillation resists the ant-fibrillation
treatment of second or third line, IABP [19] therapy shall
be initiated and immediately after that shall follow heart
catheterization and reperfusion treatment.
Patients with ventricular aneurysms and fibrillations
with three-vessel disease where CABG is possible have
shown good survival outcomes. However, fibrillation has
remained in 30% of the cases [20], except if the
aneurysm undergoes some type of surgery [21,22].
IABP in “high risk cases” to support low cardiac output
syndrome of patients undergoing cardiac surgery
In the early 70’s Berger et al. [23] and Goldman et al.
[24] realized that a major indication for the IABP use is
cardiac dysfunction after a cardiac intervention. They
consider the possibility of urgent use of IABP after car-
diac intervention, when all reasons of incomplete reper-
fusion have been eliminated and weaning from the
cardiopulmonary device is difficult, with hypotension
and low heart index despite the increased requirements
of inotropic support.
In 2001, the Benchmark registry [18] shows that the
IABP was used preoperatively in 13% of high-risk
patients. It was then became apparent that firstly the
definition of “high-risk” patient is somehow arbitrary
and secondly that it is possible that preoperative IABP
insertion in high-risk patients undergoing CABG may
decrease mortality [25]. In a very important report from
the Benchmark registry [26] the decision of instituting
IABP, were compared between US and non-US centres:
a larger percentage of US patients were identified as
'early' pre-operative support for high-risk CABG' (15.9%
vs 6.6%). A smaller percentage of US patient’s vs non-US
patients were identified as 'weaning from cardiopulmon-
ary bypass' (14.3% vs 28.2%). In hospital mortality was
lower at US vs non US sites (20.1% vs 28.7%; P < 0.001).
In comparison to Benchmark, IABP at the Australian
practise [27] demonstrated a prejudice toward intrao-
perative use (34.2% versus 16.6%; P < or = 0.0001) and an
aversion to catheter laboratory support (10.6% versus
19%; P < or = 0.0001). Their outcomes demonstrate com-
parable mortality (22% versus 20,8; P = ns). As per Dyub
et al. [28] a systematic review and meta-analysis com-
pared a total of 1034 patients received preoperative
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pooled odds ratio (OR) for hospital mortality in patients
treated with preoperative IABP was 0.41 (95% CI, 0.21-
0.82, p = 0.01). Preoperative IABP was associated with
3.6% absolute risk reduction in mortality and a 59% re-
duction in the odds for mortality in high-risk patients
undergoing CABG. The evidence supports the use of
preoperative IABP in high-risk patients to reduce hos-
pital mortality. Miceli et al. [29] clearly underlying that
there is no accepted consensus on the definition of high-
risk patients who may benefit from the early use of
intraaortic balloon pump (IABP) in coronary artery by-
pass grafting (CABG). They contacted an analysis in a
population of 9000 patients in order to identify high-risk
groups that they would potentially benefit from early
IABP support. They showed that age greater than
70 years, moderate and poor left ventricular dysfunction,
previous cardiac surgery, emergency operation, left main
disease, Canadian Cardiovascular Society 3–4 class, and
recent myocardial infarction were independent risk fac-
tors for the need of IABP insertion.
Unfortunately, the definition of high-risk population is
lacking consistency in the literature and this in tern
creates a bias when it comes to the criticism of all the
relevant trials. Christenson and colleagues [4] defined
high-risk patients as those full filling at least two of the
following criteria: medically refractory unstable angina,
ejection fraction less than 0.40, left main stenosis greater
than 70%, and redo operation.
Another limitation of relevant reports is the lack of
distinction between therapeutic for preoperative cardio-
genic shock and prophylactic preoperative IABP inser-
tion. Excluding patients receiving preoperative IABP for
hemodynamic instability, shock, recent MI within 3 days,
and emergency operation, Holmann and colleagues [30]
found no survival advantage for use of prophylactic
IABP in hemodynamically stable high-risk patients, al-
though they showed a shorter hospital length of stay.
Contrary to this a recently published propensity
matched study by Lorusso et al. [31] in high-risk patients
(defined as a EuroScore > 8) did in fact demonstrate a
mortality benefit associated with preoperative prophylac-
tic IABP insertion.
Mechanical complications due to acute myocardial
infarction (1.2%)
a) IABP support for acute ischemic mitral failure: Very
often it involves the posterior papillary muscle, while
the coronary artery responsible by 80% is the right
artery. According to Wei et al., mean survival [32]
without therapy is three days.
Support with IABP, surgery of the mitral valve and
concomitant CABG improves survival rates [33].b) IABP support for acute ischemic ventricular septal
defect: In the majority of cases, cardiogenic shock
with pulmonary congestion ensues. According to
Logue et al. [34], the deterioration of the patient’s
clinical condition depends on the extent of
involvement of the right ventricle. IABP support
during the ischemic ventricular septal defect
increases the mean aortic pressure and the cardiac
performance and reduces the right ventricular and
pulmonary wedge pressure [35].
IABP as a bridge to heart transplantation / refractory
ventricular failure (7% of the cases)
Therapy with IABP reduces the meta-load improving in
this way the performance of the failed heart; up to 22%
of the candidates for heart transplantation [36], may re-
quire support with IABP as a bridge to transplantation.
Conclusion
Traditionally the indications for using IABP are unstable
refractory angina (4%); Supporting IABP therapy after a
myocardial infarction (24.5% of the cases); catheter la-
boratory support (10.5%); ischemia related to intractable
ventricular arrhythmias (4.5%); preoperative support
(14%); weaning from cardiopulmonary bypass (34%);
mechanical complications due to acute myocardial in-
farction (1.2%); refractory ventricular failure (7%); and
other (0.3%).
The increasing early use and effectiveness of the IABP
is justified and reflects the number of patients weaned
successfully from the device. The success rates are
higher in the high-risk groups, when the device was
placed early. Therefore, beyond the traditional indica-
tions we have adopted a policy of a routine “prophylac-
tic” preoperatively support with IABP in all patients with
low ejection fraction.
However, only a prospective, randomized study in
high-risk patients will really evaluate the potential merits
of such a strategy.
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